10.76  -0.07 (-0.65%)		02-27 16:00
Open: 10.85 High: 11.81 Volume: 27,124		Pre. Close: 10.83 Low: 10.5 Market Cap: 392(M)

Short term
Mid term
Targets	6-month :	14.23	1-year :	16.62
Resists	First :	12.18	Second :	14.23
Pivot price	8.99
Supports	First :	8.21	Second :	5.75
MAs	MA(5) :	10.71	MA(20) :	8.66
	MA(100) :	6.36	MA(250) :	3.8
MACD	MACD :	1	Signal :	0.7
%K %D	K(14,3) :	69.1	D(3) :	78.9
RSI	RSI(14): 68.9
52-week	High :	16.34	Low :	0.89

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ARMP ] has closed below upper band by 17.2%. Bollinger Bands are 108.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	10.84 - 10.89	10.89 - 10.92
Low:	9.95 - 10	10 - 10.04
Close:	10.74 - 10.82	10.82 - 10.9

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Wed, 25 Feb 2026
ARMP Should I Buy - Intellectia AI

Mon, 23 Feb 2026
ARMP: HC Wainwright & Co. Raises Price Target to $15 | ARMP Stoc - GuruFocus

Mon, 23 Feb 2026
Armata Pharmaceuticals (ARMP) Receives FDA Designation for AP-SA - GuruFocus

Mon, 23 Feb 2026
FDA grants special status to phage therapy for dangerous staph infections - Stock Titan

Mon, 23 Feb 2026
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PR Newswire

Tue, 13 Jan 2026
Antibiotic-resistant Staphylococcus aureus study moves to Armata Phase 3 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.